Category: Psychedelic Bulletin - Page 11 - Psychedelic Alpha

Read more about the article Psychedelic Bulletin #106 – DMT Study Skips Set and Setting; Cybin Acquires Phase 1 Study; FDA Snubs Seamless Trial Design

Psychedelic Bulletin #106 – DMT Study Skips Set and Setting; Cybin Acquires Phase 1 Study; FDA Snubs Seamless Trial Design

Post published:June 13, 2022
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin #105 – UK Won’t Foot the Bill for Spravato; Another KAP Provider Launches; Canadian Province Decriminalises Possession of MDMA and Other Drugs

Psychedelic Bulletin #105 – UK Won’t Foot the Bill for Spravato; Another KAP Provider Launches; Canadian Province Decriminalises Possession of MDMA and Other Drugs

Post published:June 3, 2022
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin #104 – Mydecine CEO Downplays Insider Activity; UC Davis Scores $2.7m to Study Non-hallucinogenic Psychedelics; Oregon Health Authority Adopts Rules

Psychedelic Bulletin #104 – Mydecine CEO Downplays Insider Activity; UC Davis Scores $2.7m to Study Non-hallucinogenic Psychedelics; Oregon Health Authority Adopts Rules

Post published:May 27, 2022
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin #103 – MAPS Phase 3 Trial On Schedule; Australia’s National Science Agency Working on Psychedelics; Death Spiral Financings

Psychedelic Bulletin #103 – MAPS Phase 3 Trial On Schedule; Australia’s National Science Agency Working on Psychedelics; Death Spiral Financings

Post published:May 22, 2022
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin #102 – Our Analysis of MindMed’s LSD for Anxiety Results; Mail-Order Ketamine May Come Under Scrutiny; Our Notes from PSYCH Symposium

Psychedelic Bulletin #102 – Our Analysis of MindMed’s LSD for Anxiety Results; Mail-Order Ketamine May Come Under Scrutiny; Our Notes from PSYCH Symposium

Post published:May 16, 2022
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin #101 – Psychedelic R&D in the UK; COMPASS Study Points to Psilocybin for Anorexia

Psychedelic Bulletin #101 – Psychedelic R&D in the UK; COMPASS Study Points to Psilocybin for Anorexia

Post published:May 6, 2022
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin: Psychedelics X Big Pharma; $23m Round for At-Home Ketamine Therapy; Psychedelics Research Review

Psychedelic Bulletin: Psychedelics X Big Pharma; $23m Round for At-Home Ketamine Therapy; Psychedelics Research Review

Post published:April 25, 2022
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin: Numinus to Enter U.S. Clinics Market; Mydecine Announces Reverse Stock-Split; Are Magic Mushrooms Giving Investors a Bad Trip?

Psychedelic Bulletin: Numinus to Enter U.S. Clinics Market; Mydecine Announces Reverse Stock-Split; Are Magic Mushrooms Giving Investors a Bad Trip?

Post published:April 15, 2022
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin: Homecoming Raises $4m Seed; Angermayer Increases atai Stake by 1m Shares; 6 Projects Readers are Working On

Psychedelic Bulletin: Homecoming Raises $4m Seed; Angermayer Increases atai Stake by 1m Shares; 6 Projects Readers are Working On

Post published:April 8, 2022
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin: Bizarre News from Across the Psychedelics Space (April 1, 2022)

Psychedelic Bulletin: Bizarre News from Across the Psychedelics Space (April 1, 2022)

Post published:April 1, 2022
Post category:Psychedelic Bulletin

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.